EE41 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A Canada Public Payer Perspective
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.347
https://www.valueinhealthjournal.com/article/S1098-3015(23)00447-3/fulltext
Title :
EE41 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A Canada Public Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00447-3&doi=10.1016/j.jval.2023.03.347
First page :
Section Title :
Open access? :
No
Section Order :
11732